News

Novalis Biotech Acceleration Modality.AI – technology that ‘self-drives’ neurological and psychiatric assessments

Novalis Biotech Acceleration Modality.AI – technology that ‘self-drives’ neurological and psychiatric assessments

Modality.AI, pioneering AI technology for assessing neurological and psychiatric conditions remotely and in clinical settings through speech and facial measurements, has received a $2.1 million...
Read more
Epigenetics company Epify progresses colorectal cancer program and files first patent application

Epigenetics company Epify progresses colorectal cancer program and files first patent application

    Maastricht, The Netherlands, July 6, 2021 - Epify announces a patent filing in the colorectal cancer (CRC) program. The patent claims multiple epigenetic...
Read more
Novalis Biotech Closes €25 Million Biotech Acceleration Fund

Novalis Biotech Closes €25 Million Biotech Acceleration Fund

Second Healthcare Fund Invests in Start-ups and Scale-ups Advancing Transformative Healthcare Technologies
Read more
RheaVita Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMV

RheaVita Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMV

Ghent, Belgium, June 2, 2021 , RheaVita Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMV
Read more
OncoDNA and myNEO Join Forces to Unlock the Power of Personalised Vaccines

OncoDNA and myNEO Join Forces to Unlock the Power of Personalised Vaccines

OncoDNA, a company specializing in precision medicine, and myNEO, an AI-driven company revolutionizing target identification within immuno-oncology, are thrilled to announce today a new collaboration in...
Read more
Enzyre announces strategic partnership with Takeda to accelerate development of pioneering diagnostic technology platform for hemophilia patients

Enzyre announces strategic partnership with Takeda to accelerate development of pioneering diagnostic technology platform for hemophilia patients

4 th March 2021, Nijmegen, Netherlands: Enzyre, which is developing breakthrough ambulant diagnostic technology...
Read more
Grapheal raises EUR1.9 million from Novalis Biotech, BPI France and private investors, as well as non-dilutive grants

Grapheal raises EUR1.9 million from Novalis Biotech, BPI France and private investors, as well as non-dilutive grants

Grapheal raises EUR1.9 million to advance development of embedded biosensing technology
Read more
Doc.ai acquired by Sharecare

Doc.ai acquired by Sharecare

28 January 2021, PALO ALTO, Calif. Doc.ai, one of the first investments of Novalis Biotech Incubation (Fund I) has been acquired by Sharecare.
Read more
Novalis Biotech Announces First Closing of its Second Healthcare Fund

Novalis Biotech Announces First Closing of its Second Healthcare Fund

23 November 2020, Ghent, Belgium, Novalis Biotech, an early stage venture capital investor in technologies to revolutionize healthcare, announced today the successful first closing of...
Read more
Novalis invests in Enzyre to support development of Enzypad, a breakthrough hand-held diagnostic and monitoring device

Novalis invests in Enzyre to support development of Enzypad, a breakthrough hand-held diagnostic and monitoring device

27 July 2020, Nijmegen, The Netherlands, Enzyre, a developer of breakthrough diagnostic technology to bring the lab to the patient...
Read more
myNEO develops universal Covid-19 vaccine with technology for cancer treatment

myNEO develops universal Covid-19 vaccine with technology for cancer treatment

02 Jul 2020, Ghent, Belgium, myNEO announces that promising Covid-19 peptides have been identified which will undergo further preclinical testing. By making smart use of...
Read more
Novalis Biotech Incubation to invest in Cergentis

Novalis Biotech Incubation to invest in Cergentis

20 May 2020, Utrecht, The Netherlands, Novalis Biotech Incubation, a Belgian venture capital investment fund, is investing seed capital in Cergentis for an undisclosed amount.
Read more
myNEO and VUB-LMCT collaborate on Covid-19

myNEO and VUB-LMCT collaborate on Covid-19

11 May 2020, myNEO collaborates with VUB-LMCT to develop assays for immunogenicity validation of predicted SARS-CoV-2 epitopes
Read more
myNEO prepares for clinical trial with Persomed for treatment of Colorectal Cancer

myNEO prepares for clinical trial with Persomed for treatment of Colorectal Cancer

27 April 2020, Persomed joint venture anounces development of a personalised colon cancer vaccine.
Read more
BioLizard in the press: Liesbeth Ceelen and Wim Van Criekinge highlight the importance of Bioinformatics

BioLizard in the press: Liesbeth Ceelen and Wim Van Criekinge highlight the importance of Bioinformatics

February 2020, Liesbeth Ceelen (Biolizard) and Novalis founder Wim Van Criekinge appear in the Belgian press, highlighting the importance of Bioinformatics.
Read more
Epify Strengthens Management Team by Appointing Leander Van Neste as Chief Scientific Officer

Epify Strengthens Management Team by Appointing Leander Van Neste as Chief Scientific Officer

Maastricht, The Netherlands, November 7, 2019 -- Epify BV is a recently established biotechnology company that translates sound epigenetic biomarker discoveries into clinical practice to...
Read more
Official launch of OHMX.bio, partner for high-throughput OMICS solutions

Official launch of OHMX.bio, partner for high-throughput OMICS solutions

Ghent, 14 October 2019. Novalis and Ghent University are proud to release OHMX.bio (www.ohmx.bio), the sixth instalment in Novalis’ portfolio of biotechnology and life sciences...
Read more
Novalis participates in financing round of FERTIGA for further expansion of the Corona Test

Novalis participates in financing round of FERTIGA for further expansion of the Corona Test

Ghent, Belgium, 09 Oct 2019. Fertiga, the Belgian female fertility company, announces the closure of its first financing round together with Novalis Biotech Incubation and...
Read more
Epify raises 500,000 Euro in seeding round

Epify raises 500,000 Euro in seeding round

Maastricht, 26 September 2019.  Epify is a recently established biotech company that translates sound epigenetic biomarker discoveries into clinical practice to help doctors improve the...
Read more
AI Meets Genome Sequencing and the Health Data Explosion to Transform Medicine

AI Meets Genome Sequencing and the Health Data Explosion to Transform Medicine

We’ve discussed the questions of “nature vs nurture”, personalized medicine and the privacy of genomics data with Dr. Wim Van Criekinge, Chief Life Science Officer...
Read more
Wobblebase genome importer from Novalis integrated in doc.ai medical data platform

Wobblebase genome importer from Novalis integrated in doc.ai medical data platform

In October 2018, Wobblebase’s genome importer has been integrated in the doc.ai platform. Biotech incubator Novalis is now the second largest external shareholder in doc.ai.
Read more
MyNeo has been officially launched today!

MyNeo has been officially launched today!

Ghent, 27th December 2018. MyNeo has started its life as an independent entity! MyNeo is a Belgian biotech company, based in Ghent, focused on identifying,...
Read more
Launch of BioLizard’s website, lizard.bio!

Launch of BioLizard’s website, lizard.bio!

Today we announce the launch of lizard.bio, where we describe our experience in bioinformatics, biostatistics and machine learning, applied to the biotechnology field.
Read more
De Tijd interviews Novalis’s founders

De Tijd interviews Novalis’s founders

De Tijd journalist Jan De Schamphelaere discusses the launch of Novalis with our founders, from their previous careers to the current state of the fund.
Read more
Novalis founds first three companies

Novalis founds first three companies

We are proud to announce to the world the incorporation of BioLizard, OHMX.bio and MyNeo.
Read more
Novalis becomes a member of flanders.bio

Novalis becomes a member of flanders.bio

Novalis makes its entry in the Flemish biotech scene, and invites resumés to fill various positions. We’re also interested in learning about your latest research,...
Read more
Tijd article gives extra weight to Novalis’ mission

Tijd article gives extra weight to Novalis’ mission

Met een stroom positief nieuws kregen we de voorbije week weer een biotechbonanza. Jo Bury en Rudy Dekeyser, de founding fathers van het Vlaams Instituut...
Read more